Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Background Craniopharyngiomas, primary brain tumors of the pituitary–hypothalamic axis,
can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …

Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …